Naomi joined Sofinnova as an Analyst in 2024. She focuses on biopharmaceutical company investments in multiple disease areas and therapeutic modalities.
Prior to joining Sofinnova, Naomi completed her PhD in Bioengineering at Stanford University in the lab of Dr. Howard Chang. Her research focused on epigenomics and gene regulation in health and disease, leveraging methods including CRISPR epigenetic editing and single-cell sequencing. She also studied the epigenetic underpinnings of a rare autoimmune disease. During her PhD, she held leadership roles in the Stanford Biotech Group and Mythos Biotechnology Fund student-run organizations, worked as life sciences consultant with Biotech Connection Bay Area, and was a Sofinnova Venture Fellow.
Naomi earned her PhD in Bioengineering from Stanford University. She completed a BS in Biological Chemistry and BA in Chemistry from the University of Chicago where she did research on nanomaterials and immunoengineering in the School of Molecular Engineering and played for the NCAA Women’s Soccer Team.